Quarterly Earnings

The tech firm announced progress on a major health contract, but with its stock near all-time lows, can this deal deliver a much-needed turnaround?

With 43% YoY growth, Cato Networks is outpacing the SASE market. A new acquisition and key hires signal a deep focus on securing the AI era.

Intellia Therapeutics prepares for a critical March, where it will outline its gene editing future to investors amid safety questions and market pressures.

The bioprocessing leader posted robust 2025 earnings, outperforming the market with strategic innovation and a major expansion into Asian markets.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

The powertrain giant crushed market expectations with a 29% revenue surge in 2025, fueled by heavy-duty engines, while eyeing a global and green future.

The cannabis giant upsizes its credit facility by CAD $15M, signaling strong lender confidence and fueling its ambitious global expansion plans.

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

With a new CEO and a key investor conference ahead, Metagenomi bets on its unique metagenomics platform and a hemophilia drug to navigate a tough market.

The company's revenue skyrocketed, but SEC filings reveal a story of significant liquidity risks and a bold gamble on the booming wellness market.

As demand for high-speed data soars, a tiny but crucial component gets a major upgrade, enabling the next wave of 5G, IoT, and cloud technologies.

Toymaker JAKKS Pacific launches an ambitious new platform targeting the multi-billion dollar anime, manga, and creator markets. Can it beat the competition?

With its stock under pressure, Geron will face investors to defend its RYTELO sales strategy and address delays in its pivotal myelofibrosis trial.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.

With a novel skin drug launched, Pelthos Therapeutics heads to a key conference. Can its focused strategy convince Wall Street of its blockbuster potential?

With key investor conferences looming, Phathom Pharmaceuticals is set to showcase strong VOQUEZNA sales and a clear path to 2026 profitability.

A2Z Cust2Mate reports a pivotal quarter with up to $5.2M in Q4 revenue, as the delivery of over 2,000 AI-powered smart carts begins to pay off.

Armed with $320M in new capital, Anteris will showcase its revolutionary biomimetic heart valve to top investors. Can it disrupt a market of giants?

First Horizon's financial and credit chiefs will present at a key conference. We dive into their strategy amid industry headwinds and strong 2025 results.